PubMed HealthSearch

PubMed · 6779376

Lead modelling--a decision-making tool.

Abstract

The difficulties of decision-making in a state of ignorance regarding the problem area, true for many questions of environmental pollution, are discussed with reference to lead. Before irrevocably committing a considerable amount of both capital and material resources, the policy-making wound like to make a prediction as to the potential effectiveness of any control measure. To this end a mathematical model is suggested which represents the transport of lead within a standard man. It may be used at two discrete levels, either to analyse a number of control strategies in terms of their relative effectiveness in reducing blood lead concentrations, or, dependent upon the model's accuracy and the availability of data concerning the exposure to, and metabolism of, lead by a specific population, to select between two, or more, directly competing strategies for the control of that population's lead exposure, the selection of the optimum strategy being based on the model's output. Modelling may be seen, therefore, to satisfy, at least in part, the need for decision-making information in an area where time may not permit the acquisition of appropriate, unequivocable scientific evidence.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J E McEvoy. 1980. Lead modelling--a decision-making tool.. https://doi.org/10.1016/0048-9697(80)90107-2

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial.

In an effort to determine the total one-year cost of liver transplantation, the underlying drivers of that cost, and any cost differences between alternative immunosuppressive regimens, an analysis was performed comparing the average one-year posttransplant charges of 322 patients participating in the "U.S. Multi-center Prospective Randomized Trial Comparing FK-506 to Cyclosporine in Liver Transplantation." Total one-year inpatient charges including all readmissions were examined. Professional fees and outpatient charges were excluded. Costs for tacrolimus drug and blood assays were assumed to be equal to those in the CsA group. For patients completing the study, the tacrolimus group had an average length of stay and average one-year cost seven days (P = .06) and $19,290 (P = .05) lower than the CsA group. The difference in rejection profiles between the two arms seems to largely account for the lower costs. The tacrolimus arm consistently had fewer patients in the more severe rejection groups. Increased incidence and severity of rejection were directly related to higher average lengths of stay and costs of transplantation (P < .001). Tacrolimus immunosuppression during the first year after liver transplantation is more cost-effective than CsA in achieving similar patient and graft survival rates. Differing incidence and severity of rejection can dramatically affect the first-year cost of liver transplantation.

Cost-Benefit Analysis